Verzenio is a prescription medication used to treat certain types of hormone receptor-positive and HER2-negative breast cancer in adults, including early-stage and advanced or metastatic forms of the ...
INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy ...
Thanks to two FDA nods, Eli Lilly’s Verzenio doesn’t need results from a biomarker test to treat certain patients with early breast cancer, and it can reach metastatic disease regardless of menopausal ...
INDIANAPOLIS, June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary ...
Verzenio (abemaciclib) is a prescription drug that’s used to treat certain breast cancers. Verzenio can cause side effects that range from mild to serious. Examples include weight loss, diarrhea, hair ...
Verzenio (abemaciclib) is a brand-name drug prescribed for certain types of breast cancer in adults. Verzenio comes as an oral tablet that’s typically taken twice per day. Verzenio belongs to a drug ...
Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results